Review articleBeyond Cisplatin (cas 15603-27-1): Combination therapy with arsenic trioxide

Add time:09/05/2019    Source:sciencedirect.com

Platinum drugs (cisplatin, oxaliplatin, and carboplatin) and arsenic trioxide are the only commercial inorganic non-radioactive anticancer drugs approved by the US Food and Drug Administration. Numerous efforts are underway to take advantage of the synergy between the anticancer activity of cisplatin and arsenic trioxide - two drugs with strikingly different mechanisms of action. These include co-encapsulation of the two drugs in novel nanoscale delivery systems as well as the development of small molecule agents that combine the activity of these two inorganic materials. Several of these new molecular entities containing Pt-As bonds have broad anticancer activity, are robust in physiological buffer solutions, and form stable complexes with biopolymers. This review summarizes results from a number of preclinical studies involving the combination of cisplatin and As2O3, co-encapsulation and nanoformulation efforts, and the chemistry and cytotoxicity of the first member of platinum anticancer agents with an arsenous acid moiety bound to the platinum(II) center: arsenoplatins.

We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers

Prev:ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to Cisplatin (cas 15603-27-1)
Next:Review articleCisplatin (cas 15603-27-1): The first metal based anticancer drug)